Today is the official presentation of the International Ph.D. Training Program and personalities involved in the program will give us some details about it.
IDIBELL launches its International Ph.D. Training Program Read More »
At IDIBELL we know that research saves lives. That is why we work every day to do our bit in the search for a new treatment, a new method for early detection or understanding cancer-related processes.
A group from IDIBELL, CIBEREHD and UB shows that mice that do not express the NOX4 protein recover liver tissue more quickly after resection.
Depletion of NOX4 protein improves liver regeneration Read More »
An international study has developed a new algorithm that classifies a wide range of sarcomas according to their molecular patterns.
A new algorithm classifies different types of sarcoma Read More »
Researchers from IDIBELL and ICO have participated in a multicenter study, published in Nature Genetics, which shows that the implantation of human tumors in nude mice does not lead to additional DNA changes.
Xenograft Animal Models Recapitulate Genetic Behavior of Original Human Tumors Read More »
Aptadel Therapeutics is a preclinical company co-founded by IDIBELL focused on developing a new platform for targeted therapy against cancer.
Aptadel, the new IDIBELL’s spinoff Read More »
The study lead by Columbia University, in collaboration with IDIBELL and ICO, analysed thousands of tumours. They found that the key genetic programs necessary for the survival of cancer cells are controlled by only 24 modules, each one comprising only a handful of Master Regulators proteins working in concert.
Cancer’s Key Vulnerabilities found by Big Data Analysis Read More »
2020 is coming to its end, a year with great difficulties and challenges. However, this year, more than ever, we have proved the strength of our research.
A team from IDIBELL has deciphered the molecular mechanisms responsible for resistance to EGFR inhibitors and offers new therapeutic strategies.
Results, released simultaneously at the American Heart Association (AHA) 2020 virtual conference and in the journal The Lancet, show that patients who received the iron supplement were 26% less likely to be readmitted to the hospital for heart failure compared to the control group.
Iron treatment reduces the risk of hospitalization in people with heart deficiencies Read More »
